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The pharmaceutical market has some unique specifications in
healthcare economics. It has to provide its products to the health systems
and usually has to get its profits from reimbursement systems. But both
health and reimbursement markets are rather different from free markets
in terms of their official rules and being categorized as “market failure”.
In such conditions, the first thought that comes to mind is that
pharmaceutical activities are somehow dependent on health system
indicators. With this thought, we tried to seek any correlation between
pharmaceutical market size and some main health indicators in some
Middle East and Asian countries in central Asia. Most of the countries
included in the study are categorized as low or middle income countries.
The primary data were acquired from the World Bank and World Health
Organization and are summarized in Table I. Data were analysed using
SPSS 6.
Correlation analysis by Pearson’s correlation coefficient (PC) showed that
spending on health in the countries strongly depends on their gross domestic
product (GDP) per capita (PC = 0.957, p < 0.01). Adult mortality rate (PC = 
–0.615, p < 0.01), under five year mortality rate (PC = –0.416, p < 0.05), life
expectancy (PC = 0.632, p < 0.01) and healthy life expectancy (PC = 0.654, 
p < 0.01) have a significant correlation with spending on health. Vaccination
does not show any significant correlation with health spending.
A significant correlation is seen between per capita pharmaceutical con  -
sumption (total market/population) and GDP per capita (PC = 0.646, 
p < 0.01) and health spending per capita (PC = 0.781, p < 0.01).
Per capita pharmaceutical consumption shows a significant correlation
with adult mortality rate (PC = –0.522, p < 0.01), under five year mortality
rate (PC = –0.410, p < 0.05), life expectancy (PC = 0.562, p < 0.01), and
healthy life expectancy (PC = 0.581). The number of physicians has no
significant correlation with any health indicators or even the pharma  -
ceutical market (p < 0.01).
These results shows that the development process of a country in the
region and growth of GDP per capita have strongly raised health
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expenditures, but this increase has a small effect
on health indicators (PCs < 0.65). Other studies
have shown the same results but all of them
criticized the correlation between GDP and health
indicators because of age, urbanization and other
structures of the countries [1, 2].
The pharmaceutical market has been extended
by growth in GDP and health budgets but this
extension had a small effect on health indicators.
This idea is confirmed when there is no correlation
between the pharmaceutical market and the
number of physicians as the main prescriber of
pharmaceuticals. This may be due to three main
reasons:
1) The percentage of generic medicines on the
market is not equal in these countries. For
example, a generic market in a country such as
Iran could provide medicines at a lower price 
[3-5] than a branded market such as that of the
United Arab Emirates. Since the expenditures
have been compared in this study, we cannot
determine the generic share in the market and
exact utilization of medicines. If there is a clarified
national medicine policy in these countries it is
possible to estimate the share of generic
medicines in the market.
2) Usually in these countries physicians do not take
responsibility for the affordability of medicines.
In some further developed countries in the region
the government or governmental insurance
systems compensate medical costs but in others
there is no financing system to make a fair
payment system for patients. In most countries
of the region, the national drug regulatory bodies
register medicines regardless of other health
system priorities, causing a double pharma  -
ceutical market in these countries. In addition,
a public market with many defects or private
markets with a lot of overlooked affordability
problems are other concerns that need attention.
3) There are different burdens of disease between
these countries and elasticity of medication is
different between the diseases [6]. So it changes
the contribution of medicines in household
baskets. 
Therefore to have a secure pharmaceutical
market, all health indicators from community health
should be specially considered to implement an
evidence-based national drug policy. This needs an
effective strategy to recognize all health indicators
such as exact rates of diseases and adverse drug
reactions, demands, resources and opportunities.
Community health initiatives must be scientifically
sound, culturally acceptable, and managerially
feasible in developing countries [7] but current
evidence within the studies countries is not yet
sufficient to generate proper actions. Lack of proper
national health indicators may also result in
inappropriate use of drugs, causing serious adverse
reactions in organs such as skin [8] or kidney [9]. It
is very important to emphasize conducting proper
meta-analysis studies that would result in better
understanding of places where the most often sold
drugs such as antibiotics [4] are used in common
diseases such as irritable bowel syndrome that may
not necessarily need antibiotic therapy [10].
We strongly believe that it is essential for the
study countries to merge national health and drug
policies to obtain benefits in the health of their
whole population, not restricted to patients.
Powerful public insurance or social security systems
that use scientific and clarified procedures for
registration and selection of cost-effective
medicines for formularies can help.
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